FTC Reaches Proposed Settlement With CVS Caremark
Change
The Federal Trade Commission reached a proposed settlement with CVS Caremark over allegations that its pharmacy benefit manager inflated insulin prices and impeded access to the diabetes treatment.
Why it matters
The FTC filed a document indicating a proposed settlement with CVS Caremark resolving allegations that the company's PBM inflated insulin prices and impeded access. The proposed agreement is subject to review and approval by the FTC chair. CVS has said final terms are pending and expects the settlement process to conclude in the coming weeks. The matter follows a final settlement last month between the FTC and another large PBM, Express Scripts, and originates from an FTC complaint filed in September 2024 against multiple PBMs.
Implications
- • Raises settlement exposure tied to the liability finding
- • Adds a compliance obligation for affected operators
Unlock the decision layer.
See what the change means — implications, exposure, timing — and ask AI about any brief instantly.
- Implications: What actually changes downstream.
- Who is affected: Which teams or operators are exposed.
- What to watch: Deadlines, triggers, and next moves.
- Ask AI: Clarify any brief instantly, in context.
14-day free trial. Full access. No credit card required.
Start free trial
Source
Topics